GSA Capital Partners’s Lipocine LPCN Stock Holding History

GSA Capital Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48K	Buy	+18,666	New	+$44.9K	﹤0.01%	1660
2022 Q1	–	Sell	-25,908	Closed	-$437K	–	1642
2021 Q4	$437K	Buy	25,908 +7,360	+40%	+$137K	0.05%	687
2021 Q3	$344K	Buy	18,548 +10,223	+123%	+$226K	0.04%	926
2021 Q2	$198K	Buy	8,325 +914	+12%	+$21.5K	0.02%	1188
2021 Q1	$190K	Sell	7,411 -3,530	-32%	-$102K	0.03%	921
2020 Q4	$253K	Buy	10,941 +6,246	+133%	+$150K	0.04%	837
2020 Q3	$113K	Buy	4,695 +1,144	+32%	+$30.4K	0.02%	1114
2020 Q2	$76K	Buy	+3,551	New	+$46K	0.04%	515

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GSA Capital Partners's LPCN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Lipocine (LPCN) in Q2 2026: 18,666 shares worth $48K. The stake represents ﹤0.01% of the portfolio and ranks #1660 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in LPCN as recently as Q4 2021.

GSA Capital Partners first reported a position in LPCN in Q2 2020 and has held it in 8 quarters since. The position peaked at $437K in Q4 2021. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

GSA Capital Partners held 18,666 shares of Lipocine worth $48K as of Q2 2026.
Lipocine was a new GSA Capital Partners position in Q2 2026.
Lipocine made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1660 holding.
GSA Capital Partners first reported a position in Lipocine in Q2 2020 and has held it in 8 quarters since.
GSA Capital Partners's Lipocine position peaked at $437K in Q4 2021.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.